Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: An open-label, single-arm, multicenter, pilot study

BMC Gastroenterology

Volumn 17, Issue 1, 2017, Pages

  Honda, Yasushi ^a   Kessoku, Takaomi ^a   Sumida, Yoshio ^b   Kobayashi, Takashi ^a   Kato, Takayuki ^a   Ogawa, Yuji ^a   Tomeno, Wataru ^a   Imajo, Kento ^a   Fujita, Koji ^a   Yoneda, Masato ^a   Kataoka, Koshi ^a   Taguri, Masataka ^a   Yamanaka, Takeharu ^a   Seko, Yuya ^c   Tanaka, Saiyu ^d   Saito, Satoru ^a   Ono, Masafumi ^e   Oeda, Satoshi ^f   Eguchi, Yuichiro ^f   Aoi, Wataru ^g   Sato, Kenji ^h   Itoh, Yoshito ^c   Nakajima, Atsushi ^a   more..

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d Nara City Hospital   (Japan)

^e KOCHI MEDICAL SCHOOL   (Japan)

^f SAGA UNIVERSITY HOSPITAL   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY   (Japan)

^h KYOTO UNIVERSITY   (Japan)

Author keywords

Controlled attenuation parameter; Glutathione; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; FATTY ACID; FERRITIN; GLUTATHIONE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DIET; DRUG EFFICACY; ECHOGRAPHY; EXERCISE; FATTY ACID BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; HEPATIC ENCEPHALOPATHY; HUMAN; LIFESTYLE MODIFICATION; LIVER FIBROSIS; MALE; MULTICENTER STUDY; NONALCOHOLIC FATTY LIVER; PILOT STUDY; THERAPY EFFECT; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY; AGE; AGED; BLOOD; DIAGNOSTIC IMAGING; ELASTOGRAPHY; LIVER; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGE FACTORS; AGED; ALANINE TRANSAMINASE; ELASTICITY IMAGING TECHNIQUES; FATTY ACIDS, NONESTERIFIED; FEMALE; FERRITINS; GLUTATHIONE; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 85027101267     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-017-0652-3     Document Type: Article

References (29)

1. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50:585-8.
2. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28:339-50.
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-19.
4. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-23.
5. Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31.
6. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121-9.
7. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact. 1998;111-112:1-14.
8. Dentico P, Volpe A, Buongiorno R, et al. Glutathione in the treatment of chronic fatty liver diseases. Recenti Prog Med. 1995;86:290-3. [in Italian]
9. Altomare E, Colonna P, D'Agostino C, et al. High-dose antioxidant therapy during thrombolysis in patients with acute myocardial infarction. Curr Ther Res Clin Exp. 1996;57:131-41.
10. Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17:827-33.
11. Kovacs-Nolan J, Rupa P, Matsui T, et al. In vitro and ex vivo uptake of glutathione (GSH) across the intestinal epithelium and fate of oral GSH after in vivo supplementation. J Agric Food Chem. 2014;62:9499-506.
12. Park EY, Shimura N, Konishi T, et al. Increase in the protein-bound form of glutathione in human blood after the oral administration of glutathione. J Agric Food Chem. 2014;62:6183-9.
13. Seko Y, Sumida Y, Tanaka S, et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res. 2015;45:E53-61.
14. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212-28.
15. Sandrin L, Tanter M, Gennisson JL, et al. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control. 2002;49:436-46.
16. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705-13.
17. Sanyal AJ, Chalasani N, Kowdley KV, et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85.
18. Zhou X, Han D, Xu R, et al. Glycine protects against high sucrose and high fat-induced non-alcoholic steatohepatitis in rats. Oncotarget. 2016;7:80223-37.
19. Mardinoglu A, Bjornson E, Zhang C, et al. Personal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD. Mol Syst Biol. 2017;13:916.
20. Souza MR, Diniz Mde F, Medeiros-Filho JE, et al. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49:89-96.
21. Aoi W, Ogaya Y, Takami M, et al. Glutathione supplementation suppresses muscle fatigue induced by prolonged exercise via improved aerobic metabolism. J Int Soc Sports Nutr. 2015;12:7.
22. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol. 2007;102:1251-8.
23. Lapenna D, Pierdomenico SD, Ciofani G, et al. Association of body iron stores with low molecular weight iron and oxidant damage of human atherosclerotic plaques. Free Radic Biol Med. 2007;42:492-8.
24. Dongiovanni P, Valenti L, Ludovica Fracanzani A, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008;172:738-47.
25. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
26. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842-57.
27. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2011;306:1549-56.
28. Shi KQ, Tang JZ, Zhu XL, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014;29:1149-58.
29. Pharmaceutical Interview Form, Japan Standard Commodity No. 873922, 2014.